Yale study shows pre- and post-surgery chemotherapy extends survival for 15-20% of operable pancreatic cancer patients.

Yale study finds pancreatic cancer patients who receive chemotherapy both before and after surgery have longer survival rates than expected from surgery followed by chemotherapy. The research, published in JAMA Oncology, involved patients with pancreatic ductal adenocarcinoma, a common form of pancreatic cancer. The findings are encouraging for the 15-20% of operable pancreatic cancer patients.